Raptor May Obtain European Regulatory Nod for Rare Disease Drug Procysbi

Compiled by Andrew Berens, MD, Senior Healthcare Analyst, Grace Guo, Bloomberg Industries and Elizabeth Krutoholow


Raptor may secure a second regulatory nod this week for its drug Procysbi, which treats a rare disease known as for nephropathic cystinosis.


The company won FDA approval for the medicine for the treatment of the rare metabolism error late last month after the original approval date was extended by three months.


Read more >>>


Bloomberg BRIEF Newsletters